collaborate
collaborators
funding partners
affiliations
areas of collaboration
antigen discovery | development
adjuvant discovery | development |
delivery
product development
drug discovery
Chembio's long and successful history with IDRI is testimony to their superior antigen discovery skills and global network of expertise. This, combined with our mutual commitment to global health and a complementary approach in our research and development collaborations together, has produced outstanding results.
Lawrence Siebert, CEO, Chembio Diagnostic Systems, Inc.
| |
Adjuvant Discovery | Development | Delivery
Our Adjuvant and Delivery team has been developing and studying novel adjuvants for use in vaccines for many threats to human health including the flu, TB and HIV/AIDS. We have discovered new molecules based on bacterial and viral surfaces that effectively trigger key alarm systems in the body. These systems, known as Toll-like receptors (TLRs), can be safely exploited to formulate adjuvants that will generate powerful and long-lived immune responses to safe subunit vaccines. Our work in this field has generated numerous publications and interest from governments and companies that would like to develop effective vaccination strategies with few side effects.
The method of delivering the antigen-adjuvant mixture also has significant impact on vaccine potency. Some of the different delivery systems we are examining include emulsions, liposomes, naked DNA, and adenoviral vectors.
We are interested in pursuing relationships with others who have novel adjuvant or delivery technologies, as well as relationships with those who can utilize our proprietary adjuvants in their product development efforts.
|
